title: Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity of lung dysfunction in ARDS patients.
abstract: Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) are severe forms of bilateral lung inflammation with poor clinical outcomes. However, the pathophysiology of ALI/ARDS remains largely obscure. Soluble receptor for advanced glycation endproducts (sRAGE) plays a key regulatory role during the acute phase of inflammation, and baseline plasma levels of sRAGE were recently found to be associated with severity of ALI/ARDS. We analyzed, in ALI/ARDS patients, plasma and alveolar levels of sRAGE over time and the association with severity of lung injury. We enrolled 21 ALI/ARDS patients admitted to our intensive care unit (ICU) and assayed plasma sRAGE on the first 2 days after diagnosis, every three days for the first month and then once a week, until ICU discharge or death. We also measured sRAGE levels in bronchoalveolar lavage fluids, obtained when clinically indicated. At each sampling time, we recorded physiological and clinical data of the patients. Plasma sRAGE levels peaked at day 1 and decreased over time. When all samples were considered, plasma and alveolar sRAGE levels were significantly higher in patients with worse oxygenation and higher need for ventilatory support (i.e., patients with more severe lung dysfunction). Moreover, the presence of lung infection yielded higher alveolar sRAGE levels. In conclusion, we show that the plasma and alveolar levels of sRAGE in ALI/ARDS patients are correlated to lung injury severity and to lung infection. Our findings may, in time, lead to the development of more effective therapies against ALI/ARDS.
authors.affiliation: Department of Experimental Medicine, University of Milan-Bicocca, San Gerardo Hospital, Via Pergolesi 33, Monza, Italy.
authors.forename: Tommaso
authors.initials: T
authors.lastname: Mauri
authors.forename: Serge
authors.initials: S
authors.lastname: Masson
authors.forename: Andrea
authors.initials: A
authors.lastname: Pradella
authors.forename: Giacomo
authors.initials: G
authors.lastname: Bellani
authors.forename: Andrea
authors.initials: A
authors.lastname: Coppadoro
authors.forename: Michela
authors.initials: M
authors.lastname: Bombino
authors.forename: Sonia
authors.initials: S
authors.lastname: Valentino
authors.forename: Nicoló
authors.initials: N
authors.lastname: Patroniti
authors.forename: Alberto
authors.initials: A
authors.lastname: Mantovani
authors.forename: Antonio
authors.initials: A
authors.lastname: Pesenti
authors.forename: Roberto
authors.initials: R
authors.lastname: Latini
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011650:Pulmonary Alveoli / Q000378:metabolism* / Q000503:physiopathology; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000032:analysis / Q000378:metabolism*; D012128:Respiratory Distress Syndrome / Q000378:metabolism* / Q000503:physiopathology; D012129:Respiratory Function Tests; D000683:Serum Amyloid P-Component / Q000032:analysis; D012720:Severity of Illness Index; D000099153:Pentraxins
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D000683:Serum Amyloid P-Component; D000099153:Pentraxins